Journal Browser

► Journal Browser

Design and Development of Novel Responsive Carrier for Drug Delivery

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 6497

Share This Special Issue

Special Issue Editor

Prof. Dr. Jinqiang Wang

E-Mail Website
Guest Editor

College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China
Interests: polymeric carrier; drug delivery; stimuli-responsive; biomaterials; devices

Special Issue Information

Dear Colleagues,

Advanced drug delivery technology has been widely explored for the precise treatment of diseases. The pathological structures and signals of the diseased sites are the generally used targets of drug delivery systems. Precisely matching the responsiveness of the carrier to the pathological signal is a prerequisite for the design of an ideal drug delivery system. Therefore, pathological signal discovery and the design of responsive carriers are both critical for obtaining proper formulations. This issue will focus on the pathological signals and the associated newly developed disease-targeting carriers.

In this light, pathological signals including ROS, acidic environment, inflammation signals, cell types, enzymes, and antigens represent the widely used stimuli for the design of the disease-targeting formulations. Drug carriers including liposomes, polymeric micelles, polymers, antibodies, cell-based carriers, cell-membrane particles, exosomes, microneedle array patch, and inorganic nanoparticles all represent efficient carriers to selectively deliver drugs, including small chemical molecules, proteins, DNA, and RNA, to the targeting diseased sites. As such, this Special Issue welcomes submissions from researchers in the field of medical science and drug delivery, including original research and review articles related to pharmaceutic science, material science, life science, medical science, and biomedical engineering.

Prof. Dr. Jinqiang Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Biomaterials
Nanotechnology
Theragnostic
Disease targeting
Drug delivery Stimuli-responsive
Nanoparticles
Signal-responsive
Responsive carriers
Pathological signal
Drug conjugates

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

14 pages, 2022 KiB

Open AccessArticle

Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin

by Muhammad Israr, Nicola Pugliese, Arshad Farid, Shakira Ghazanfar, Alessandro Di Cerbo, Muhammad Muzammal, Abdulhakeem S. Alamri, Syed Mohammed Basheeruddin Asdaq, Ashfaq Ahmad and Kamran Ahmad Khan

Molecules 2022, 27(10), 3242; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27103242 - 18 May 2022

Cited by 11 | Viewed by 2644

Abstract

Controlled-release effervescent floating bilayer tablets reduce dosage frequency and improve patient compliance with enhanced therapeutic outcomes. Generally, two different tablets of clarithromycin and esomeprazole, respectively, are given for the treatment of Helicobacter pylori infection and it might be worth incorporating both in a single tablet. In the current study, controlled-release floating bilayer tablets of clarithromycin and esomeprazole (F1–F4) were developed with different rates of polymeric materials by a direct compression method. During the formulation, Fourier-transform infrared spectroscopy (FTIR) analysis was performed for possible interactions between drugs and excipients. No interactions between drugs and excipients were noted. Moreover, the bilayer tablets’ thickness, diameter, friability, hardness, weight variation, dissolution, and percent purity were found within the acceptable limits. The floating lag time and total floating time of all formulations were found to be < 25 s and 24 h, respectively. The release of both the clarithromycin and esomeprazole started at the same time from the controlled-release floating bilayer tablets by anomalous non-Fickian diffusion, and the polymeric materials extended the drug release rate up to 24 h. In the case of F1, the results approached ideal zero-order kinetics. The dissolution profiles of the tested and reference tablet formulations were compared, but no significant differences were observed. It can be concluded that such controlled-release effervescent floating bilayer tablets can be efficiently used in clinical practice to reduce dosage frequency and increase patient compliance with continuous drug release for 24 h, which ultimately might enhance therapeutic efficacy. Full article

(This article belongs to the Special Issue Design and Development of Novel Responsive Carrier for Drug Delivery)

► Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1723 KiB

Open AccessReview

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

by Xu Lin, Jiahe Wu, Yupeng Liu, Nengming Lin, Jian Hu and Bo Zhang

Molecules 2022, 27(3), 948; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27030948 - 30 Jan 2022

Cited by 13 | Viewed by 3331

Abstract

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Numerous drugs have been developed to treat lung cancer patients in recent years, whereas most of these drugs have undesirable adverse effects due to nonspecific distribution in the body. To address this problem, stimuli-responsive drug delivery systems are imparted with unique characteristics and specifically deliver loaded drugs at lung cancer tissues on the basis of internal tumor microenvironment or external stimuli. This review summarized recent studies focusing on the smart carriers that could respond to light, ultrasound, pH, or enzyme, and provided a promising strategy for lung cancer therapy. Full article

(This article belongs to the Special Issue Design and Development of Novel Responsive Carrier for Drug Delivery)

► Show Figures